{"id":11375,"date":"2018-05-09T15:23:57","date_gmt":"2018-05-09T13:23:57","guid":{"rendered":"https:\/\/www.bm-t.de\/v4\/2021\/inflarx-raises-another-63-mio-in-primary-shares\/"},"modified":"2018-05-09T15:23:57","modified_gmt":"2018-05-09T13:23:57","slug":"inflarx-raises-another-63-mio-in-primary-shares","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2018-en\/inflarx-raises-another-63-mio-in-primary-shares\/","title":{"rendered":"InflaRx raises another $ 63 Mio in primary shares"},"content":{"rendered":"<p><strong>InflaRx and cur\u00adrent share\u00adhold\u00aders placed $ 117,3 Mio. of shares, with $ 63 Mio. as pri\u00admary shares with the pro\u00adceeds going to InflaRx and $ 54 Mio. as sec\u00adondary shares with the pro\u00adceeds going to early share\u00adhold\u00aders, who all remain invested in InflaRx<\/strong><\/p>\n<p>The NASDAQ listed com\u00adpany, InflaRx NV (Nas\u00addaq: IFRX) from Jena informed the mar\u00adkets of a pri\u00admary and sec\u00adondary share place\u00adment in total of $ 117,3 Mio. $ 63 Mio. worth of shares were sold as pri\u00admary shares with the pro\u00adceeds going to InflaRx and $ 54 Mio. worth of shares were sold by exist\u00ading share\u00adhold\u00aders as sec\u00adondary shares. All sell\u00ading share\u00adhold\u00aders remain invested in InflaRx.<\/p>\n<p>InflaRx devel\u00adops ther\u00ada\u00adpies for the treat\u00adment of inflam\u00adma\u00adtion-related mal\u00adadies, which tar\u00adget the com\u00adple\u00adment sys\u00adtem, a key com\u00adpo\u00adnent of the body\u00b4s nat\u00adural immune sys\u00adtem. InflaRx intends to use&nbsp;the pro\u00adceeds from the cap\u00adi\u00adtal raise to finance the fur\u00adther clin\u00adi\u00adcal devel\u00adop\u00adment of its lead can\u00addi\u00addate IFX\u20111, which is cur\u00adrently in Phase&nbsp;IIb.<\/p>\n<p>The ther\u00adapy is being tri\u00adaled on patients with mod\u00ader\u00adate to advanced Hidradeni\u00adtis Sup\u00adpu\u00adra\u00adtiva (HS), which is a painful and chronic inflam\u00adma\u00adtory skin dis\u00adease with cur\u00adrently lim\u00adited treat\u00adment options. Fur\u00adther\u00admore, the com\u00adpound is going to be tested in two phase II tri\u00adals for addi\u00adtional auto-immune and inflam\u00adma\u00adtion indications.<\/p>\n<p>bm|t beteili\u00adgungs\u00adman\u00adage\u00adment Th\u00fcrin\u00adgen GmbH is proud to have been the lead investor in InflaRx since day&nbsp;one.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>InflaRx and cur\u00adrent share\u00adhold\u00aders placed $ 117,3 Mio. of shares, with $ 63 Mio. as pri\u00admary shares with the pro\u00adceeds going to InflaRx and $ 54 Mio. as sec\u00adondary shares with the pro\u00adceeds going to early share\u00adhold\u00aders, who all remain invested in InflaRx The NASDAQ listed com\u00adpany, InflaRx NV (Nas\u00addaq: IFRX) from Jena informed the&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[147],"tags":[],"class_list":["post-11375","post","type-post","status-publish","format-standard","hentry","category-2018-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=11375"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11375\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=11375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=11375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=11375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}